Hille Andrea, Christiansen Hans, Pradier Olivier, Hermann Robert Michael, Siekmeyer Birgit, Weiss Elisabeth, Hilgers Reinhard, Hess Clemens F, Schmidberger Heinz
Department of Radiotherapy and Radiation Oncology, University of Goettingen, Germany.
Strahlenther Onkol. 2005 Sep;181(9):606-14. doi: 10.1007/s00066-005-1390-y.
Chronic radiation proctitis/enteritis is a relevant complication of pelvic irradiation, which is still mainly treated by supportive measures only. There is some evidence that the combined treatment with pentoxifylline and tocopherol might alter the pathogenesis of radiation-induced fibrosis. In a retrospective analysis the clinical benefit of the treatment with pentoxifylline/tocopherol on radiation-induced proctitis/enteritis was evaluated, compared to supportive care only.
Of 30 patients with radiation-induced proctitis/enteritis grade I-II according to the RTOG/EORTC toxicity criteria, 21 were treated with pentoxifylline and tocopherol. Depending on physician's decision nine patients received symptomatic treatment only.
With pentoxifylline/tocopherol treatment 15/21 patients (71%) experienced a relief of their symptoms. A reduction from grade I/II to grade 0 toxicity was observed in seven and from grade II to grade I toxicity in eight patients. No improvement was seen in six patients. The median time to improvement with pentoxifylline and tocopherol treatment was 28 weeks. In three of nine patients who were treated supportively only, deterioration of symptoms occurred. Three patients experienced no amelioration, and three patients with grade I toxicity experienced a spontaneous relief of their symptoms (33%).
The combination treatment with pentoxifylline and tocopherol seems to have a benefit in patients with grade I-II radiation-induced proctitis/enteritis. The optimal schedule of treatment duration is not yet clear. From the observations made in this study it is assumed the treatment should be given for 6-12 months at least. A prospective phase II study should be undertaken to evaluate optimal treatment duration.
慢性放射性直肠炎/肠炎是盆腔放疗的一种相关并发症,目前仍主要仅采用支持性措施进行治疗。有证据表明,己酮可可碱与生育酚联合治疗可能会改变放射性纤维化的发病机制。在一项回顾性分析中,评估了己酮可可碱/生育酚治疗放射性直肠炎/肠炎相对于仅采用支持性治疗的临床益处。
根据RTOG/EORTC毒性标准,30例I-II级放射性直肠炎/肠炎患者中,21例接受了己酮可可碱和生育酚治疗。根据医生的决定,9例患者仅接受了对症治疗。
接受己酮可可碱/生育酚治疗的21例患者中有15例(71%)症状得到缓解。7例患者的毒性从I/II级降至0级,8例患者从II级降至I级。6例患者未见改善。己酮可可碱和生育酚治疗后症状改善的中位时间为28周。仅接受支持性治疗的9例患者中有3例症状恶化。3例患者症状未改善,3例I级毒性患者症状自行缓解(33%)。
己酮可可碱和生育酚联合治疗似乎对I-II级放射性直肠炎/肠炎患者有益。最佳治疗疗程尚不清楚。根据本研究的观察结果,推测治疗应至少持续6至12个月。应开展一项前瞻性II期研究以评估最佳治疗疗程。